$1,318.00
Thyroid eye disease (TED), also called Graves’ ophthalmopathy or orbitopathy, is an autoimmune disorder that causes inflammation in the orbital and retroocular tissues. It generally occurs as a manifestation of Graves’ disease, a condition in which the immune system attacks the thyroid gland, commonly affecting the eyes and skin. Although TED is usually found in Graves’ hyperthyroidism patients, some patients may have autoimmune euthyroid or hypothyroid thyroiditis. TED is mostly a mild, non-progressive, and self-limiting disease; however, in rare cases it can progress to vision loss. The negative impact of TED on the social and psychological well-being of individuals is an established consequence of the disease.
This Market Spotlight report covers the Thyroid Eye Disease (TED) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Definition
7 Patient segmentation
9 Symptoms
9 Risk factors
10 Diagnosis
11 TREATMENT
11 Medical treatment
11 Orbital radiotherapy
11 Surgical treatment
13 EPIDEMIOLOGY
13 Thyroid eye disease occurrence in thyroid disorders
13 Incidence methodology
17 MARKETED DRUGS
19 PIPELINE DRUGS
23 KEY UPCOMING EVENTS
24 KEY REGULATORY EVENTS
24 With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business
25 PROBABILITY OF SUCCESS
26 REVENUE OPPORTUNITY
27 CLINICAL TRIAL LANDSCAPE
28 Sponsors by status
28 Sponsors by phase
30 BIBLIOGRAPHY
31 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of thyroid eye disease, 2020–29
19 Figure 2: Overview of pipeline drugs for TED in the US
19 Figure 3: Pipeline drugs for TED, by company
19 Figure 4: Pipeline drugs for TED, by drug type
20 Figure 5: Pipeline drugs for TED, by classification
23 Figure 6: Key upcoming events in thyroid eye disease
25 Figure 7: Probability of success in the ophthalmology-other pipeline
27 Figure 8: Clinical trials in thyroid eye disease
27 Figure 9: Top 10 drugs for clinical trials in thyroid eye disease
28 Figure 10: Top 10 companies for clinical trials in thyroid eye disease
28 Figure 11: Thyroid eye disease trials status
29 Figure 12: Thyroid eye disease trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalence of thyroid eye disease in Graves’ disease
14 Table 2: Incident cases of thyroid eye disease, 2020–29
18 Table 3: Marketed drugs for thyroid eye disease
21 Table 4: Pipeline drugs for TED in the US
26 Table 5: Historical global sales, by drug ($m), 2016–20
26 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!